Literature DB >> 17552039

Pain relief in osteoarthritis: patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications.

Chris G Richardson1, Andrew Chalmers, Hilary A Llewellyn-Thomas, Alice Klinkhoff, Anne Carswell, Jacek A Kopec.   

Abstract

OBJECTIVE: Information concerning patients' preferences for the treatment of osteoarthritis (OA) is limited. We examined patients' attitudes toward the acceptability of gastrointestinal, cardiac, and cerebrovascular events in order to obtain pain relief from OA.
METHODS: Patients responded to a set of threshold technique tasks. Each task described 2 treatment options, their levels of pain relief, and the risks of side effects. The risk for the side effect under investigation was then systematically increased to reveal the maximal acceptable risk increment associated with the pain reduction.
RESULTS: Of 196 patients, 22.3% and 14.7% were unwilling to accept any additional risk of stomach bleed or heart attack/stroke for 2-point and 5-point pain reductions, respectively. Patients were willing to accept significantly more risk for a 5-point pain reduction than for a 2-point pain reduction in stomach bleed and heart attack/stroke scenarios. Patients also accepted significantly greater additional risks of stomach bleed compared to heart attack/stroke for 2-point and 5-point pain reductions.
CONCLUSION: Most patients with OA are willing to accept some additional risk of stomach bleed and heart attack/stroke to gain pain relief. Patients are willing to accept greater additional risk of stomach bleed than heart attack/stroke. However, there exists considerable variation in risk-taking attitudes across patients. We recommend that clinicians examine the risk attitude and treatment preferences of each patient on an individual basis when deciding on a treatment regimen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552039

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations.

Authors:  Bethea A Kleykamp; Robert H Dworkin; Dennis C Turk; Zubin Bhagwagar; Penney Cowan; Christopher Eccleston; Susan S Ellenberg; Scott R Evans; John T Farrar; Roy L Freeman; Louis P Garrison; Jennifer S Gewandter; Veeraindar Goli; Smriti Iyengar; Alejandro R Jadad; Mark P Jensen; Roderick Junor; Nathaniel P Katz; J Patrick Kesslak; Ernest A Kopecky; Dmitri Lissin; John D Markman; Michael P McDermott; Philip J Mease; Alec B O'Connor; Kushang V Patel; Srinivasa N Raja; Michael C Rowbotham; Cristina Sampaio; Jasvinder A Singh; Ilona Steigerwald; Vibeke Strand; Leslie A Tive; Jeffrey Tobias; Ajay D Wasan; Hilary D Wilson
Journal:  Pain       Date:  2021-09-09       Impact factor: 7.926

2.  Understanding preferences for disease-modifying drugs in osteoarthritis.

Authors:  Liana Fraenkel; Lisa Suter; Charles E Cunningham; Gillian Hawker
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-08       Impact factor: 4.794

Review 3.  Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.

Authors:  Inger L Meek; Mart A F J Van de Laar; Harald E Vonkeman
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-07

Review 4.  Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use.

Authors:  Sebastian Straube; Martin R Tramèr; R Andrew Moore; Sheena Derry; Henry J McQuay
Journal:  BMC Gastroenterol       Date:  2009-06-05       Impact factor: 3.067

5.  Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS).

Authors:  Tracey-Lea Laba; Jo-anne Brien; Marlene Fransen; Stephen Jan
Journal:  BMC Musculoskelet Disord       Date:  2013-05-06       Impact factor: 2.362

Review 6.  What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs.

Authors:  R Andrew Moore; Sheena Derry; Henry J McQuay; John Paling
Journal:  Arthritis Res Ther       Date:  2008-02-07       Impact factor: 5.156

Review 7.  Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk.

Authors:  Robert Andrew Moore; Sheena Derry; Lee S Simon; Paul Emery
Journal:  Pain Pract       Date:  2013-08-14       Impact factor: 3.183

8.  Determinants for acceptance of preventive treatment against heart disease - a web-based population survey.

Authors:  Nielsen Jesper Bo; Jarbøl Dorte Ejg; Gyrd-Hansen Dorte; Barfoed Benedicte Marie Lind; Larsen Pia Veldt
Journal:  BMC Public Health       Date:  2014-08-02       Impact factor: 3.295

Review 9.  Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?

Authors:  Christian Cadet; Emmanuel Maheu
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-18       Impact factor: 5.346

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.